Compare Intuitive Surgical, Inc. (ISRG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs 10X Genomics Inc — how do they compare? Intuitive Surgical, Inc. trades at $354.5 (market cap $125.08B), while 10X Genomics Inc trades at $42.5 (market cap $5.48B). The key difference: Intuitive Surgical, Inc. is far larger — about 22.8× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ISRG | TXG | |
|---|---|---|
Market Cap | $125.08B | $5.48B |
Sector | Health | Health |
52-Week High | $592.85 | $45.80 |
52-Week Low | $345.42 | $11.34 |
Enterprise Value | $116.45B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $354.00, up 2.48% today, but remains near its 52-week low of $344.55. The stock faces technical bearish pressure despite strong Q2 2026 earnings beats, with revenue reaching $10.06B in 2025 and net income margin at 28.45%. Recent news highlights investor concerns over moderated U.S. procedure growth and a cautious 2026 outlook, driving the stock's recent decline.
The outlook balances robust fundamentals against near-term headwinds. Wall Street maintains a bullish consensus price target of $504.56, but risks include slowing procedure growth and insurance-related challenges. Long-term growth drivers like global da Vinci adoption and AI integration offer upside, though volatility may persist amid sentiment shifts.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
